Preferred antiretroviral drugs for the next decade of scale up

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Andrieux Meyer, Isabelle ^a   Calmy, Alexandra ^a,b   Cahn, Pedro ^c   Clayden, Polly ^d   Raguin, Gilles ^e,f   Katlama, Christine ^g,h   Vitoria, Marco ⁱ   Levin, Andrew ^j   Lynch, Sharonann ^a   Goemaere, Eric ^a   Ford, Nathan ^a,k  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d c o HIV i Base   (United Kingdom)

^e ESTHER   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Solthis   (France)

ⁱ UNAIDS   (Switzerland)

^j CLINTON HEALTH ACCESS INITIATIVE   (United States)

^k Centre for Infectious Disease Epidemiology and Research   (South Africa)

more..

Author keywords

Antiretroviral therapy; Regimen sequencing; Treatment optimization

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; QUAD; RALTEGRAVIR; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TENOFOVIR ALAFENAMIDE; UNCLASSIFIED DRUG;

COMORBIDITY; CONSULTATION; DEVELOPING COUNTRY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FRACTURE; FREEZING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESPAN; LOW DRUG DOSE; MEDICATION COMPLIANCE; MIXED INFECTION; NANOTECHNOLOGY; NEPHROTOXICITY; NOTE; PALATABILITY; PATIENT COUNSELING; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; SCALE UP; THERMOSTABILITY; TREATMENT FAILURE; TUBERCULOSIS; VIRUS HEPATITIS; VIRUS LOAD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; PRACTICE GUIDELINE; REVIEW;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS;

EID: 84872869308     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17986     Document Type: Note

References (23)

1. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS - United Nations General Assembly Resolution 65/277. New York, United Nations; 2011.
2. Progress report 2011. Global HIV/AIDS response Epidemic update and health sector progress towards universal access. WHO, UNICEF, UNAIDS. Geneva, Switzerland: December 2011.
3. US Food and Drugs Administration. Antiretroviral drugs used in the treatment of HIV infection, 2012. Available from: http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm122951.htm
4. Lynch S, Ford N, van Cutsem G, Bygrave H, Janssens B, Decroo T. Getting HIV treatment to the most people. Science 2012;337(6092):298-300.
5. Antiretroviral Sequencing Meeting Report. MSF. Geneva, 2011. Available from: http://www.msfaccess.org/content/antiretroviral-sequencing-meeting-report
6. WHO/UNAIDS. The treatment 2.0 framework for action: catalyzing the next phase of treatment, care and support. Geneva, Switzerland: World Health Organization; 2011.
7. WHO. Short-term priorities for antiretroviral drug optimization: meeting report. Geneva, Switzerland: World Health Organization; 2011.
8. WHO. Consultation: the strategic use of antiretrovirals for treatment and prevention of HIV. Geneva, Switzerland: WHO; 2011.
9. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
10. Mills E, Bakanda C, Birungi J, Chan K, Ford N, Cooper C, et al. Life expectancy of individuals on combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-16.
11. Calmy A, Klement E, Teck R, Berman D, Pécoul B, Ferradini L, et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling up. AIDS. 2004;18:2353-60.
12. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16(10):1297-313
13. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.
14. MSF/UNAIDS. Closer to home: delivering antiretroviral therapy in the community. Experience from four countries in Southern Africa. Geneva, Switzerland: MSF/UNAIDS; 2012.
15. Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;1:38-47.
16. Ford N, Calmy A, Mofenson L. Safety of efavirenz in first-trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301-4.
17. WHO. Technical update on treatment optimization: use of efavirenz during pregnancy in a public health perspective. Geneva, Switzerland: World Health Organization; 2012. Available from: http://extranet.who.int/iris/bitstream/ 10665/70920/1/9789241503792-eng.pdf
18. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825-31.
19. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
20. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C, participants of Conference on Antiretroviral Drug Optimization. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis. 2012;12(7):550-60.
21. Loeliger A, Suthar A, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2011;16(1):6-15.
22. Clayden P, Collins S, Daniels C, Geffen N, Harrington M, Jefferys R, et al. 2012 Pipeline report. HIV, HCV and TB, drugs, diagnostics, vaccines, and preventive technologies in development. London, UK: i-Base/Treatment Action Group; 2012.
23. Safety and efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 single tablet regimen versus Cobicistat-boosted Darunavir plus Emtricitabine/Tenofovir Disoproxil Fumarate fixed dose combination in HIV-1 infected, antiretroviral treatment naive adults. ClinicalTrials.gov Identifier: NCT01565850.